HWP
JAZZ icon

Highline Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Highline Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Hold
48
– – ﹤0.01% 533
2026
Q1 		$9.07K Buy
+48
New +$8.39K ﹤0.01% 488
2025
Q2 		– Sell
-3
Closed -$372 – 989
2025
Q1 		$372 Buy
+3
New +$391 ﹤0.01% 882

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Highline Wealth Partners's JAZZ Position: Q2 2026 in Review

Highline Wealth Partners held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 48 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #533.

Highline Wealth Partners first reported a position in JAZZ in Q1 2025 and has held it in 3 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Highline Wealth Partners held 48 shares of Jazz Pharmaceuticals worth $11.6K as of Q2 2026.
  • Highline Wealth Partners left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #533 holding.
  • Highline Wealth Partners first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.